CareDx Responds To Natera's Filing Of A Motion For An Injunction Related To Patent 11,111,544; CareDx Informed Natera And The Court, Since August 2023, CareDx Has Utilized A New Allosure Process That It Believes Does Not Infringe On The '544 Patent.
CareDx Responds To Natera's Filing Of A Motion For An Injunction Related To Patent 11,111,544; CareDx Informed Natera And The Court, Since August 2023, CareDx Has Utilized A New Allosure Process That It Believes Does Not Infringe On The '544 Patent.
CareDx Reiterates Position that it Does Not Infringe Natera's '544 Patent
CaredX 重申其不侵犯 Natera '544 專利的立場
Injunction Motion has No Impact on CareDx's Business or Patient and Clinician Access to AlloSure or AlloMap
禁令動議對CaredX的業務或患者和臨床醫生獲得AlloSure或AlloMap的機會沒有影響
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today responded to Natera, Inc.'s filing of a motion for an injunction related to patent 11,111,544 (the '544 patent).
CareDx, Inc.（納斯達克股票代碼：CDNA）——移植公司專注於爲移植患者和護理人員發現、開發和商業化具有臨床差異化的高價值醫療保健解決方案——今天對Natera, Inc.做出了回應。正在提交與專利11,111,544號（'544號專利）相關的禁令動議。
The motion seeks to stop CareDx from using a prior AlloSure process that Natera alleged infringed the '544 patent. That process is no longer in effect. As CareDx informed Natera and the Court, since August 2023, CareDx has utilized a new AlloSure process that it believes does not infringe on the '544 patent.
該議案旨在阻止CaredX使用先前的AlloSure程序，納泰拉指控該程序侵犯了'544年專利。該程序已不再有效。正如CaredX告知納特拉和法院的那樣，自2023年8月以來，CaredX一直在使用新的AlloSure程序，它認爲該程序沒有侵犯'544年專利。
The underlying validity of the '544 patent also remains subject to judicial review.
'544專利的基本有效性也仍有待司法審查。
"We believe the motion against a process that is no longer in effect is irrelevant, and the District Court is still considering the fundamental question of the validity of the '544 patent," said John W. Hanna, CareDx President and CEO. "We greatly appreciate the continued support of the transplant community as we seek to resolve these matters, allowing us to return our full attention to serving patients and developing clinical innovations that improve transplant care."
CaredX總裁兼首席執行官約翰·漢納表示：“我們認爲，反對已失效程序的動議無關緊要，地方法院仍在考慮'544年專利有效性的根本問題。”“我們非常感謝移植界在我們尋求解決這些問題時給予的持續支持，這使我們能夠將全部精力重新放在爲患者提供服務和開發改善移植護理的臨床創新上。”
Natera has previously claimed infringement on three patents:
Natera此前曾聲稱侵權了三項專利：
- Prior to trial, the District Court dismissed patent 10,597,724 (the '724 patent) as invalid as patent ineligible.
- At trial, CareDx was found not to have infringed on patent 10,655,180 (the '180 patent).
- The '544 patent is the subject of post-trial motion practice in which, among other things, CareDx is seeking to invalidate that patent on the same grounds as the '724 patent.
- 在審判之前，地區法院駁回了10,597,724號專利（'724專利）無效，因爲該專利不符合資格。
- 在審判中，CaredX被認定沒有侵犯10,655,180號專利（'180年專利）。
- '544專利是審後動議實踐的主題，除其他外，CaredX正尋求以與'724專利相同的理由宣佈該專利無效。
Natera's motion does not impact CareDx's business or ability to continue providing transplant patients with AlloSure or AlloMap.
納泰拉的動議不會影響CaredX的業務或繼續爲移植患者提供AlloSure或AlloMap的能力。
譯文內容由第三人軟體翻譯。